FOLH1 expression

Multiple similarities between BET and VISION eligibility criteria (V + /B +) prior to [177Lu]Lu-PSMA RLT were observed, with the majority of patients fulfilling both. Positivity in both criteria was associated with the best outcome. Data from our pilot cohort suggest that the criteria for BET's phase I trial select patients more strictly for [177Lu]Lu-PSMA RLT than VISION criteria, while OS did not significantly differ between the three different groups.

Study findings will be disseminated through peer-reviewed publications and conference presentations. 2025-520482-52-03 (https://euclinicaltrials.eu/ctis-public/view/2025-520482-52-03?lang=en, protocol nr 6.0).

The hematological parameters remained stable for the whole period of observation. The presented clinical case report describes a unique positive experience on the use of [225Ac]Ac-PSMA-617 therapy in mCRPC and brain meningioma, thus allowing us to expand our understanding of PSMA RLT as a method for the treatment of not only prostatic tumors but also tumors of non-prostatic locations.

In this pilot cohort, concomitant ARSi therapy did not significantly enhance tumor absorbed doses in patients receiving [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T RLT. Further prospective studies with larger patient numbers are needed to evaluate the impact of concomitant ARSi treatment on the absorbed doses in mCRPC tumor lesions.

Our large-scale study of transcriptome demonstrates FOLR2 gene expression is associated with aggressive prostate cancer in samples with low expression of PSMA. Future prediction of disease risk could be enhanced by using FOLR2 as a molecular target for identifying aggressive prostate cancer in cases of low PSMA.

Although the initiation of cytotoxicity was kinetically slower than the αCD3 scFv counterpart, αTCR VHH CSANs achieved comparable end point cytotoxicity across multiple antigen densities, as well as in 3D tumor spheroids. Through this study we demonstrate the applicability of nanobodies as T-cell targeting domains, enhanced specificity and safety of moderate affinity T-cells binders and the diversification of T-cell targeting epitopes without compromising the efficacy of TCEs.

We highlight physiologic and pathologic variations in PSMA uptake, common diagnostic pitfalls, and characteristic imaging changes after androgen-deprivation therapy, radiation, and prostatectomy. By relating anatomy, molecular physiology, and treatment effects to PSMA PET findings, this article provides nuclear medicine practitioners with a practical foundation to improve diagnostic accuracy and optimize patient selection for PSMA-based imaging and therapy.

The ENZA-p trial is a randomized phase 2 trial of enzalutamide versus enzalutamide ± lutetium-177 ([177Lu])Lu-PSMA-617 in mCRPC, which demonstrated a significant improvement in overall survival and quality of life with this combination compared to enzalutamide monotherapy [1,2]. Transational endpoints of the trial embedded at inception were designed to better understand the relationship between androgen blockade and PSMA expression and its potential impact on clinical outcomes. This mini-review will discuss the genetics of PSMA receptor expression, the preclinical evidence for androgen/PSMA receptor interaction, and the frequency, magnitude, and clinical significance of PSMA expression change in response to androgen blockade with enzalutamide.

Across heterogeneous and often heavily pretreated populations, lutetium-177 PSMA-617 demonstrated consistent clinical benefit, with a tolerable safety profile...Our mini review focuses on results in early-access programs. These findings support the effectiveness and manageable safety of RLT in routine practice, including in more complex cases that are often excluded from trials.

To dissect the underlying mechanism, the authors performed high-resolution single-cell RNA sequencing of murine BM.HBOC treatment markedly expanded mature neutrophils, plasmacytoid dendritic cells, classical monocytes, natural killer T cells, and mature B cells, while concomitantly upregulating DNA damage repair genes such as Parp9, Dtx3l, and Smchd1 within these subsets. Gene set enrichment analysis confirmed significant activation of DNA damage response pathways, implying enhanced cellular radioresistance and improved tolerance to β-particle irradiation. Thus, HBOCs improve 177Lu-PSMA-617 antitumor efficacy indirectly via immune-subset expansion and DNA-repair reinforcement, offering a clinically feasible and safe strategy to optimize combination protocols for patients with mCRPC.

This study highlights FOLH1's pan-cancer expression patterns and nominates melatonin as an exploratory therapeutic candidate for prostate cancer requiring further mechanistic validation. Our integrated computational-experimental framework highlights the promise of AI-driven drug discovery in oncology, while emphasizing the need for further mechanistic validation.

PSMA-RADS-4 represents an optimal positivity threshold for [¹⁸F]PSMA-1007 PET/CT, providing superior diagnostic performance compared with CT and BS and supporting its clinical utility for standardized image interpretation.